Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2024; 30(33): 3810-3817
Published online Sep 7, 2024. doi: 10.3748/wjg.v30.i33.3810
Published online Sep 7, 2024. doi: 10.3748/wjg.v30.i33.3810
Colorectal cancer cell dormancy: An insight into pathways
Anil Kumar, Lekha Saha, Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: Kumar A and Saha L contributed to this paper; Kumar A and Saha L designed the overall concept and outline of the manuscript; Saha L contributed to the discussion and design of the manuscript; Kumar A contributed to the writing and editing the manuscript, illustrations, and review of the literature.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lekha Saha, Doctor, MBBS, MD, Professor, Department of Phar
Received: May 20, 2024
Revised: July 23, 2024
Accepted: July 26, 2024
Published online: September 7, 2024
Processing time: 104 Days and 19.1 Hours
Revised: July 23, 2024
Accepted: July 26, 2024
Published online: September 7, 2024
Processing time: 104 Days and 19.1 Hours
Core Tip
Core Tip: Colorectal cancer (CRC) cell dormancy drives therapeutic resistance, recurrence, and metastasis. Key molecular pathways involved in CRC dormancy include Hippo/YAP, NANOG, HIF-1α, Notch, ERK/MAPK, AKT, Wnt, and SMAD. Dysregulation of these pathways promotes dormancy. After re-entering active tumor state following dormancy, these cancer cells become more aggressive and metastasize quickly. The mechanisms behind CRC dormancy are largely unexplored. This editorial summarizes these pathways and their interactions, highlighting the identification of predictive biomarkers crucial for developing targeted therapies, overcoming drug resistance, and enhancing personalized treatments and patient outcomes.